Salugen's HAVEOS Genetics Test - either the two-gene screen or 12-gene in-depth genetic profile test are both highly predictive of excess craving behaviors due to neurotransmitter imbalance. In a published study in the Journal of Royal Science, the Salugen HAVEOS Genetics Test was found to have a 74% Positive Predictive Value for these types of behaviors. Compared to cholesterol testing's predictive value for cardiovascular disease (which is 40% positive predictive value), the Salugen HAVEOS Genetics test is almost twice as predictive of substance abuse and aberrant craving behaviors when compared to commonly accepted cholesterol testing.* 

Salugen has a very secure processes around the use of DNA that is outlined in our Informed Consent and Privacy Policy (click here).  Salugen's Clinical Reference Laboratory is a state-of-the-art facility with all the appropriate licenses and standards to perform this testing.  Salugen's processes are consistent with the Genetic Information Non-Discrimination Act which prohibits employers and insurers from using genetic information in hiring decisions or insurance eligibility.    Your DNA results are shared confidentially with your physician and clinical team to ensure you have the best care possible.

If you have a genetic risk to substance abuse or tolerance, it is purely a risk.  Environmental triggers, such as prescription pain killers, pain or stress may trigger the chemical imbalances which lead to excess cravings and stress.  If you have this risk, you and your treating physician should consider this information, along with your medical history and current diagnosis to adjust your threapy appropriately.  For some patients, a physician may elect to more closely monitor a patient on prescription pain medication who has a genetic predisposition.  For patients already on high doses of prescription pain medication, a physician may elect to reduce the pain medication and prescribe alternative pain management treatments that do not present a risk for addiction. A patient should always consult with a medical professional before making any decision about their medical treatment.

The Salugen System is a cost-effective way to identify patients who may be at greater risk for substance abuse and tolerance, or to confirm a genetic risk in patients who are already displaying symptoms of tolerance or abuse.  By knowing the genetic information early in the episode of care, a clinician and insurance company can make better choices in the treatment plan to avoid the costly and long-lasting problems associated substance abuse and tolerance.  By identifying the genetic information later in the episode of care when a patient may need to consider medical detoxification, a physician and insurer can effective detox the patient and prescribe a maintenance therapy to avoid relapse by addressing the genetic predisposition to chemical imbalance that will remain after detoxification.  In both situation, Salugen helps the payer avoid the rapidly escalating costs of pharmaceutical treatment failure and the physician avoid the liability and professional disappointment in having a patient become an addict.

No, Salugen, Inc. was a nutritional genomics company focused on providing DNA-customized nutritional solutions.  In late 2009, Salugen, Inc. ceased business operations and some limited assets were acquired by Salugen Biosciences for its business. Salugen Biosciences is a biotechnology company offering laboratory testing such as genetic and urine drug testing, medical detoxification, and wellness products.